• Wondering if Labcorp Holdings at around US$258 a share still offers value, or if most of the opportunity is already priced in? This article walks through the key signals you can use to judge that for yourself.
• The stock has been fairly steady over the last week with a 0.5% return, has a 4.1% decline over the past month, yet sits on a 4.8% return over 1 year and 41.6% over 3 years. This raises the question of whether the current price reflects the business fundamentals.
• Recent headlines around Labcorp have focused on its role in broader healthcare trends and the ongoing demand for diagnostic and laboratory services. This helps frame how investors think about its resilience and growth options. These themes give context to why the stock can show shorter term pullbacks, such as the recent 30 day move, while still retaining interest over multi year periods.
• Labcorp currently scores 5 out of 6 on Simply Wall St's valuation checks, and you can see the breakdown of that valuation score here. Next it is worth walking through the main valuation methods used in that assessment and then circling back to an even richer way to think about what the stock might be worth.

Approach 1: Labcorp Holdings Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts them back to today’s dollars to estimate what the entire business could be worth now.

For Labcorp Holdings, the model used is a 2 Stage Free Cash Flow to Equity approach, built on cash flow projections. The company’s last twelve month free cash flow is about $1.31b. Simply Wall St uses analyst estimates where available, such as projected free cash flow of $908.55m in 2024, then extends that with its own assumptions out to 2035. By 2035, the model is using a projected free cash flow figure of $2.16b, with each year’s cash flow discounted back to today.

When all those discounted cash flows are added together and divided by the number of shares, the DCF model suggests an intrinsic value of about $531.91 per share, compared with a current share price around $258. That implies the stock is roughly 51.5% undervalued on this measure.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Labcorp Holdings is undervalued by 51.5%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Labcorp Holdings Price vs Earnings (P/E)

The P/E ratio is a common way to value profitable companies because it directly links what you pay for the stock to the earnings the company is currently generating. Higher growth expectations and lower perceived risk usually justify a higher P/E, while lower growth and higher risk tend to support a lower, more conservative P/E.

Labcorp Holdings currently trades at a P/E of 22.47x. That sits close to the broader Healthcare industry average of 22.13x and below the peer group average of 30.67x, so on simple comparisons the stock is not priced at the top of its sector.

Simply Wall St also calculates a “Fair Ratio” of 23.73x for Labcorp, which is the P/E level suggested by its own model after considering factors such as earnings growth, profit margins, industry, market cap and risk profile. This Fair Ratio can be more informative than a straight peer or industry comparison because it tries to match the multiple to the company’s specific characteristics rather than broad group averages. With the current P/E of 22.47x sitting below the Fair Ratio of 23.73x, the stock screens as undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Labcorp Holdings Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you connect your view of Labcorp Holdings, such as whether collaborations, new tests, AI tools and cost programs can support the revenue, margin and earnings assumptions behind a fair value like US$310.06, to a forecast and then to a fair value that you can compare with the current price. Each Narrative sits on the Community page, updates automatically as new news or earnings arrive, and allows different investors to land at different fair values, for example closer to the higher US$340 or the lower US$270 analyst targets, depending on how they rate the same information.

Do you think there's more to the story for Labcorp Holdings? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.